Miriplatin | A lipophilic derivative of cisplatin | CAS#141977-79-9

MedKoo Cat#: 128985 | Name: Miriplatin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Miriplatin (MPT) is a novel platinum complex used in TACE that shows promise for the treatment of hepatocellular carcinoma (HCC). Miriplatin is a lipophilic platinum complex that can be easily suspended in Lipiodol and gradually releases active platinum compounds in tumor tissue. Miriplatin is less severe toxicity profile compared to other platinum anticancer agents.

Chemical Structure

Miriplatin

CAS#141977-79-9 (free base)

Theoretical Analysis

MedKoo Cat#: 128985

Name: Miriplatin

CAS#: 141977-79-9 (free base)

Chemical Formula: C34H68N2O4Pt

Exact Mass: 763.4827

Molecular Weight: 764.01

Elemental Analysis: C, 53.45; H, 8.97; N, 3.67; O, 8.38; Pt, 25.53

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 550.00	2 Weeks
25mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

250159-48-9 (hydrate) 141977-79-9 (free base)

Synonym

Miriplatin; SM-11355; SM11355; SM 11355

IUPAC/Chemical Name

(SP-4-2)-[(1R,2R)-1,2-cyclohexanediamine-κN1,κN2]bis(tetradecanoato-κO)-platinum

InChi Key

BGIHRZPJIYJKAZ-BLUNCNMSSA-L

InChi Code

InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1

SMILES Code

CCCCCCCCCCCCCC([O-][Pt+2]1([O-]C(CCCCCCCCCCCCC)=O)[NH2][C@]2([C@]([H])([NH2]1)CCCC2)[H])=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 764.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yasui D, Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Kawamoto C, Uchida E, Kumita S. Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma. Biomed Res Int. 2014;2014:359296. doi: 10.1155/2014/359296. Epub 2014 Sep 8. PubMed PMID: 25276780; PubMed Central PMCID: PMC4172877. 2: Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Kakizaki S, Sato K. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol Res. 2014 Aug 8. doi: 10.1111/hepr.12403. [Epub ahead of print] PubMed PMID: 25132539. 3: Ishikawa T, Abe S, Inoue R, Sugano T, Watanabe Y, Iwanaga A, Seki K, Honma T, Nemoto T, Takeda K, Yoshida T. Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma. PLoS One. 2014 Jul 21;9(7):e103009. doi: 10.1371/journal.pone.0103009. eCollection 2014. PubMed PMID: 25047920; PubMed Central PMCID: PMC4105420. 4: Ito T, Okubo H, Kokubu S, Miyazaki A, Ando H, Fujimura A, Watanabe S. Radiofrequency ablation combined with chemolipiodolization in a porcine liver: Comparison of the pharmacokinetic analysis with cisplatin powder and miriplatin. Hepatol Res. 2014 Jul 7. doi: 10.1111/hepr.12387. [Epub ahead of print] PubMed PMID: 25040841. 5: Otsuji K, Takai K, Nishigaki Y, Shimizu S, Hayashi H, Imai K, Suzuki Y, Hanai T, Ideta T, Miyazaki T, Tomita E, Shimizu M, Moriwaki H. Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12376. [Epub ahead of print] PubMed PMID: 24961745. 6: Okimoto K, Ogasawara S, Chiba T, Ooka Y, Oobu M, Azemoto R, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Yoshikawa M, Yokosuka O. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma. Anticancer Res. 2013 Dec;33(12):5603-9. PubMed PMID: 24324105. 7: Yamanaka T, Takaki H, Nakatsuka A, Uchida K, Junji U, Fujimori M, Hasegawa T, Yoneda M, Shiraishi T, Sakuma H, Yamakado K. Radiofrequency ablation after arterial injection of miriplatin-iodized oil suspension into swine liver: ablative zone size and tissue platinum concentration. Cardiovasc Intervent Radiol. 2014 Aug;37(4):1047-52. doi: 10.1007/s00270-013-0779-8. PubMed PMID: 24232037. 8: Hashimoto N, Iwazawa J, Ohue S, Mitani T. Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy. Onco Targets Ther. 2013 Aug 1;6:1025-30. doi: 10.2147/OTT.S49443. eCollection 2013. PubMed PMID: 23986641; PubMed Central PMCID: PMC3753878. 9: Handa T, Imai Y, Sugawara K, Chikayama T, Nakazawa M, Ando S, Hamaoka K, Inao M, Nakayama N, Mochida S. Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin. Hepatol Res. 2013 Aug 19. doi: 10.1111/hepr.12225. [Epub ahead of print] PubMed PMID: 23957866. 10: Ueda T, Murata S, Yasui D, Mine T, Kumita S. Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma. Hepatol Res. 2013 Oct;43(10):1071-7. doi: 10.1111/hepr.12212. Epub 2013 Aug 19. PubMed PMID: 23905645.